{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,10]],"date-time":"2026-01-10T02:41:11Z","timestamp":1768012871934,"version":"3.49.0"},"reference-count":31,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,4,1]],"date-time":"2017-04-01T00:00:00Z","timestamp":1491004800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","schres-journal.com","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Schizophrenia Research"],"published-print":{"date-parts":[[2017,4]]},"DOI":"10.1016\/j.schres.2016.10.035","type":"journal-article","created":{"date-parts":[[2016,11,5]],"date-time":"2016-11-05T00:16:10Z","timestamp":1478304970000},"page":"98-103","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":18,"special_numbering":"C","title":["Risk of breast cancer in risperidone users: A nationwide cohort study"],"prefix":"10.1016","volume":"182","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1372-4262","authenticated-orcid":false,"given":"Johan","family":"Reutfors","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Louise","family":"Wing\u00e5rd","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lena","family":"Brandt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yiting","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hong","family":"Qiu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Helle","family":"Kieler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shahram","family":"Bahmanyar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.schres.2016.10.035_bb0005","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.psym.2013.08.008","article-title":"Psychotropic-induced hyperprolactinemia: a clinical review","volume":"55","author":"Ajmal","year":"2014","journal-title":"Psychosomatics"},{"issue":"2","key":"10.1016\/j.schres.2016.10.035_bb0010","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1007\/s10549-011-1506-2","article-title":"The use of atypical antipsychotics and the risk of breast cancer","volume":"129","author":"Azoulay","year":"2011","journal-title":"Breast Cancer Res. Treat."},{"issue":"2","key":"10.1016\/j.schres.2016.10.035_bb0015","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1530\/EJE-11-0076","article-title":"Cancer risk in hyperprolactinemia patients: a population-based cohort study","volume":"165","author":"Berinder","year":"2011","journal-title":"Eur. J. Endocrinol."},{"issue":"3","key":"10.1016\/j.schres.2016.10.035_bb0020","first-page":"692","article-title":"Progressive trabecular osteopenia in women with hyperprolactinemic amenorrhea","volume":"75","author":"Biller","year":"1992","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"7827","key":"10.1016\/j.schres.2016.10.035_bb0025","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1016\/S0140-6736(73)92102-8","article-title":"Prolactin, phenothiazines, admission to mental hospital, and carcinoma of the breast","volume":"2","author":"Brugmans","year":"1973","journal-title":"Lancet"},{"issue":"7","key":"10.1016\/j.schres.2016.10.035_bb0030","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1038\/sj.bjc.6603259","article-title":"Cancer risk among users of neuroleptic medication: a population-based cohort study","volume":"95","author":"Dalton","year":"2006","journal-title":"Br. J. Cancer"},{"issue":"2","key":"10.1016\/j.schres.2016.10.035_bb0035","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1530\/EJE-15-0282","article-title":"Breast cancer risk in hyperprolactinemia: a population-based cohort study and meta-analysis of the literature","volume":"173","author":"Dekkers","year":"2015","journal-title":"Eur. J. Endocrinol."},{"key":"10.1016\/j.schres.2016.10.035_bb0040","doi-asserted-by":"crossref","unstructured":"Edge, S.B., Carlson, R.W., 2011. Breast cancer staging: predicting outcome and response to treatment, Breast Surg. Tech. Interdisc. Manag. Springer, pp. 269\u2013285.","DOI":"10.1007\/978-1-4419-6076-4_25"},{"issue":"2","key":"10.1016\/j.schres.2016.10.035_bb0045","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1002\/cncr.29714","article-title":"Prolactin and breast cancer: the need to avoid undertreatment of serious psychiatric illnesses in breast cancer patients: a review","volume":"122","author":"Froes Brandao","year":"2016","journal-title":"Cancer"},{"issue":"20","key":"10.1016\/j.schres.2016.10.035_bb0050","doi-asserted-by":"crossref","first-page":"2291","DOI":"10.2165\/00003495-200464200-00003","article-title":"Antipsychotic-induced hyperprolactinaemia: mechanisms, clinical features and management","volume":"64","author":"Haddad","year":"2004","journal-title":"Drugs"},{"issue":"3","key":"10.1016\/j.schres.2016.10.035_bb0055","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1002\/jat.1063","article-title":"Human relevance of rodent prolactin-induced non-genotoxic mammary carcinogenesis: prolactin involvement in human breast cancer and significance for toxicology risk assessments","volume":"25","author":"Harvey","year":"2005","journal-title":"J. Appl. Toxicol."},{"issue":"1","key":"10.1016\/j.schres.2016.10.035_bb0060","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/jat.1772","article-title":"Hypothesis: prolactin is tumorigenic to human breast: dispelling the myth that prolactin-induced mammary tumors are rodent-specific","volume":"32","author":"Harvey","year":"2012","journal-title":"J. Appl. Toxicol."},{"issue":"2","key":"10.1016\/j.schres.2016.10.035_bb0065","first-page":"79","article-title":"A prospective study of endogenous hormones and breast cancer","volume":"18","author":"Helzlsouer","year":"1994","journal-title":"Cancer Detect. Prev."},{"issue":"6","key":"10.1016\/j.schres.2016.10.035_bb0070","first-page":"575","article-title":"A prospective study of estradiol and breast cancer in Japanese women","volume":"9","author":"Kabuto","year":"2000","journal-title":"Cancer Epidemiol. Biomark. Prev."},{"issue":"8","key":"10.1016\/j.schres.2016.10.035_bb0075","first-page":"785","article-title":"Phenothiazines and breast cancer","volume":"76","author":"Kanhouwa","year":"1984","journal-title":"J. Natl. Med. Assoc."},{"issue":"8","key":"10.1016\/j.schres.2016.10.035_bb0080","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1093\/oxfordjournals.aje.a010091","article-title":"Risk of breast cancer according to use of antidepressants, phenothiazines, and antihistamines","volume":"150","author":"Kelly","year":"1999","journal-title":"Am. J. Epidemiol."},{"key":"10.1016\/j.schres.2016.10.035_bb0085","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1186\/1471-2458-11-450","article-title":"External review and validation of the Swedish national inpatient register","volume":"11","author":"Ludvigsson","year":"2011","journal-title":"BMC Public Health"},{"issue":"7","key":"10.1016\/j.schres.2016.10.035_bb0090","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1023\/A:1025671317220","article-title":"Postmenopausal breast cancer risk in relation to sex steroid hormones, prolactin and SHBG (Sweden)","volume":"14","author":"Manjer","year":"2003","journal-title":"Cancer Causes Control"},{"issue":"1","key":"10.1016\/j.schres.2016.10.035_bb0095","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/S0167-8140(85)80063-3","article-title":"Some aspects on validity of breast cancer, pancreatic cancer and lung cancer registration in Swedish official statistics","volume":"4","author":"Mattsson","year":"1985","journal-title":"Radiother. Oncol."},{"issue":"12","key":"10.1016\/j.schres.2016.10.035_bb0100","first-page":"1371","article-title":"Consumption of psychopharmaceuticals in residential facilities for the elderly. Evaluation of the extent, indications and effects","volume":"98","author":"Nilsson","year":"2001","journal-title":"Lakartidningen"},{"issue":"1","key":"10.1016\/j.schres.2016.10.035_bb0105","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1007\/s10549-013-2731-7","article-title":"Reevaluation of the proposed autocrine proliferative function of prolactin in breast cancer","volume":"142","author":"Nitze","year":"2013","journal-title":"Breast Cancer Res. Treat."},{"key":"10.1016\/j.schres.2016.10.035_bb0110","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/j.psychres.2016.03.015","article-title":"Prolactin and macroprolactin levels in psychiatric patients receiving atypical antipsychotics: a preliminary study","volume":"239","author":"Park","year":"2016","journal-title":"Psych. Res."},{"issue":"12","key":"10.1016\/j.schres.2016.10.035_bb0115","doi-asserted-by":"crossref","first-page":"5555","DOI":"10.1210\/endo.138.12.5605","article-title":"Expression of prolactin and its receptor in human breast carcinoma","volume":"138","author":"Reynolds","year":"1997","journal-title":"Endocrinology"},{"issue":"1","key":"10.1016\/j.schres.2016.10.035_bb0120","doi-asserted-by":"crossref","first-page":"9","DOI":"10.3322\/caac.21208","article-title":"Cancer statistics, 2014","volume":"64","author":"Siegel","year":"2014","journal-title":"CA Cancer J. Clin."},{"issue":"7","key":"10.1016\/j.schres.2016.10.035_bb0125","doi-asserted-by":"crossref","first-page":"1422","DOI":"10.1093\/annonc\/mdu150","article-title":"Circulating prolactin and breast cancer risk among pre- and postmenopausal women in the EPIC cohort","volume":"25","author":"Tikk","year":"2014","journal-title":"Ann. Oncol."},{"issue":"2","key":"10.1016\/j.schres.2016.10.035_bb0130","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1210\/jcem.83.2.4564","article-title":"Increased expression of prolactin receptor gene assessed by quantitative polymerase chain reaction in human breast tumors versus normal breast tissues","volume":"83","author":"Touraine","year":"1998","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"15","key":"10.1016\/j.schres.2016.10.035_bb0135","doi-asserted-by":"crossref","first-page":"4810","DOI":"10.1158\/0008-5472.CAN-13-0665","article-title":"A 20-year prospective study of plasma prolactin as a risk marker of breast cancer development","volume":"73","author":"Tworoger","year":"2013","journal-title":"Cancer Res."},{"issue":"9","key":"10.1016\/j.schres.2016.10.035_bb0140","first-page":"2703","article-title":"Breast cancer at a psychiatric hospital before and after the introduction of neuroleptic agents","volume":"38","author":"Wagner","year":"1978","journal-title":"Cancer Res."},{"issue":"2","key":"10.1016\/j.schres.2016.10.035_bb0145","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1093\/ije\/21.2.214","article-title":"Relationship of blood prolactin levels and the risk of subsequent breast cancer","volume":"21","author":"Wang","year":"1992","journal-title":"Int. J. Epidemiol."},{"issue":"12","key":"10.1016\/j.schres.2016.10.035_bb0150","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1001\/archpsyc.59.12.1147","article-title":"Dopamine antagonists and the development of breast cancer","volume":"59","author":"Wang","year":"2002","journal-title":"Arch. Gen. Psychiatry"},{"issue":"7","key":"10.1016\/j.schres.2016.10.035_bb0155","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1002\/pds.1294","article-title":"The new Swedish prescribed drug register\u2013opportunities for pharmacoepidemiological research and experience from the first six months","volume":"16","author":"Wettermark","year":"2007","journal-title":"Pharmacoepidemiol. Drug Saf."}],"container-title":["Schizophrenia Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0920996416304790?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0920996416304790?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,9,15]],"date-time":"2019-09-15T05:18:21Z","timestamp":1568524701000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0920996416304790"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,4]]},"references-count":31,"alternative-id":["S0920996416304790"],"URL":"https:\/\/doi.org\/10.1016\/j.schres.2016.10.035","relation":{},"ISSN":["0920-9964"],"issn-type":[{"value":"0920-9964","type":"print"}],"subject":[],"published":{"date-parts":[[2017,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Risk of breast cancer in risperidone users: A nationwide cohort study","name":"articletitle","label":"Article Title"},{"value":"Schizophrenia Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.schres.2016.10.035","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}